Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC.
Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC.
复制标题
DOI：
10.1155/2021/5596415
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
He H
中科院分区：
文献类型：
--
作者：
Peng W;Xu Y;Feng F;Gu C;Wang Z;Han D;Zhou X;He H
华蟾素胶囊是一种抗肿瘤中成药，目前已广泛应用于晚期非小细胞肺癌（NSCLC）患者铂类化疗的后续治疗。 评价华蟾素胶囊联合铂类一线化疗治疗晚期非小细胞肺癌的疗效和安全性。研究设计.根据系统性综述和荟萃分析（PRISMA）指南的首选报告项目，对本研究选择的8项结局指标进行了系统性综述和荟萃分析。 在7个电子数据库中进行了全面的文献检索，以识别所有相关的随机对照试验。采用科克伦手册5.1.0评价纳入试验的质量，采用RevMan 5.3和Stata 15.1软件进行联合收割机数据分析和发表偏倚评价。 在回顾的19项研究中，共纳入1，564例患者。与单用一线铂类化疗相比，华蟾素胶囊联合化疗在改善ORR方面显示出显著效果（RR = 1.49，95% CI（1.33，1.66）），1年生存率（RR = 1.44，95% CI（1.28，1.63））和2年生存率（RR = 1.78，95%CI（1.42，2.22）），提高了CD 3+细胞的百分比（SMD = 1.25，95% CI（1.05，1.45）），CD 4+细胞（SMD = 1.52，95% CI（1.33，1.71））和CD 4 +/CD 8+比值（SMD = 1.36，95% CI（1.17，1.54）），并减少化疗毒性，包括白细胞减少症（RR = 0.61，95% CI（0.51，0.72））、血小板减少（RR = 0.52，95% CI（0.41，0.67））和呕吐（RR = 0.79，95% CI（0.70，0.88））。 华蟾素胶囊可提高非小细胞肺癌铂类一线化疗的疗效，改善细胞免疫功能，降低化疗毒副作用。这些结果需要进一步严格设计的随机对照试验（RCT）来证实。
Cinobufacini capsule, an anticancer traditional Chinese patent medicine, has been widely used as adjunctive treatment to platinum-based chemotherapy in patients with advanced NSCLC. To evaluate the efficacy and safety of cinobufacini capsule combined with first-line platinum-based chemotherapy for advanced NSCLC. Study Design. A systematic review and meta-analysis of eight outcome measures selected for this study were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted in 7 electronic databases to identify all the relevant randomised controlled trials. Cochrane handbook 5.1.0 was applied to evaluate the quality of included trials, and the RevMan 5.3 and Stata 15.1 software were used to combine the trials for data analysis and assess the publication bias. From the 19 studies reviewed, a total of 1,564 patients were included. Compared with first-line platinum-based chemotherapy alone, cinobufacini capsule combined with chemotherapy showed significant effects in improving ORR (RR = 1.49, 95% CI (1.33, 1.66)), 1-year survival rate (RR = 1.44, 95% CI (1.28, 1.63)), and 2-year survival rate (RR = 1.78, 95% CI (1.42, 2.22)), raising the percentages of CD3+ cells (SMD = 1.25, 95% CI (1.05, 1.45)), CD4+ cells (SMD = 1.52, 95% CI (1.33, 1.71)), and ratio of CD4+/CD8+ (SMD = 1.36, 95% CI (1.17, 1.54)), and reducing chemotherapy toxicity including leukopenia (RR = 0.61, 95% CI (0.51, 0.72)), thrombocytopenia (RR = 0.52, 95% CI (0.41, 0.67)), and vomiting (RR = 0.79, 95% CI (0.70, 0.88)). Cinobufacini capsule may increase the therapeutic effectiveness, improve cellular immune function, and reduce the toxicity of first-line platinum-based chemotherapy in patients with NSCLC. These results require confirmation by further rigorously designed randomised controlled trials (RCTs).
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
6.2
作者：
Meng, Zhiqiang;Yang, Peiying;Shen, Yehua;Bei, Wenying;Zhang, Ying;Ge, Yongqian;Newman, Robert A.;Cohen, Lorenzo;Liu, Luming;Thornton, Bob;Chang, David Z.;Liao, Zongxing;Kurzrock, Razelle
通讯作者：
Kurzrock, Razelle
DOI：
10.1155/2013/426207
发表时间：
2013
期刊：
Evidence-based complementary and alternative medicine : eCAM
影响因子：
--
作者：
He H;Zhou X;Wang Q;Zhao Y
通讯作者：
Zhao Y
影响因子：
3.7
作者：
Ichikawa M;Sowa Y;Iizumi Y;Aono Y;Sakai T
通讯作者：
Sakai T
影响因子：
5.4
作者：
Lee, Sunyeong;Lee, Younghyun;Chung, Hai Won
通讯作者：
Chung, Hai Won